• ADAKVEO®▼ (crizanlizumab)

    ADAKVEO ® (crizanlizumab) is indicated for the prevention of recurrent VOCs in patients with sickle cell disease (SCD) who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as a monotherapy in...

  • Haematology Masterclass 2021

    This meeting was organised and funded by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code.

    The Novartis Haematology Masterclass is a...

  • Haematology Masterclass 2021

    This meeting was organised and funded by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. Prescribing information for the Novartis brands mentioned during...

  • EXJADE®▼ (deferasirox)

    Raise the bar in iron chelation therapy (ICT). What is EXJADE? EXJADE is a once-daily oral iron chelator available as a FCT formulation: 1 Guidelines support the use of ICTs, such as EXJADE, for the management of iron overload in patients with MDS, SCD...
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]